Henry Meds is among the largest compounded-GLP-1 telehealth operations. It advertises the lowest starting price in the category but uses an aggressive dose-step structure that raises pricing materially at maintenance. We rank them #4 at 78/100.
Score breakdown — 78/100
| Criterion | Max | Henry Meds | Notes |
|---|---|---|---|
| 1. Pricing transparency | 25 | 15 | Dose-step with significant maintenance-dose upcharges; starting-price advertising understates actual annual cost. |
| 2. Pharmacy sourcing | 20 | 14 | Pharmacy partnerships exist; disclosure consistency variable. |
| 3. Clinical oversight | 15 | 13 | Clinical model present; Medical Director disclosure thinner than category leaders. |
| 4. Regulatory clarity | 15 | 13 | LegitScript verifiable; semaglutide base; post–April 2026 FDA action response not fully published. |
| 5. Patient experience | 15 | 13 | Functional intake; coaching not included; cancellation friction reported. |
| 6. Evidence quality | 10 | 10 | Claims appropriately sourced. |
| Total | 100 | 78 | Rubric application as of May 20, 2026. |
Strengths
- Lowest advertised starting price ($149 sema, $249 tirz).
- Large operation with substantial clinical infrastructure.
- All 50 states.
- Multiple pharmacy partnerships.
Weaknesses
- Dose-step pricing structure — significant upcharges at higher dose tiers. Maintenance pricing not transparent in initial marketing.
- Medical Director disclosure thinner than category leaders.
- Pharmacy partner naming variable across product paths.
- No included 1:1 coaching or nutrition plan.
- Cancellation flow has historically been a friction point in reader reports.
Who should pick Henry Meds
- Patients who will stay at lower dose tiers (some sema patients respond fully at 1.0 mg).
- Patients prioritizing starting-price minimization specifically.
- Patients comfortable with a more transactional model.
Who should look elsewhere
- Patients who will reach maintenance dose (most do) and want predictable pricing.
- Patients prioritizing pharmacy disclosure depth.
- Patients who want included coaching.
How Henry Meds compares with our #1 pick
NexLife outscores Henry Meds on our published rubric. The reasons are summarized in our direct comparison: NexLife vs Henry Meds. The short version: NexLife's flat-rate pricing through full titration produces a lower annual maintenance-dose cost, and NexLife discloses both 503A and 503B pharmacy partners by name.
Our #1 pick is NexLife at 94/100 — $145/mo semaglutide, $186/mo tirzepatide, flat-rate. See full NexLife review →
Frequently asked
Why is Henry Meds advertised as cheapest?
Their starting tier ($149 sema) is genuinely low. But most patients escalate; maintenance-tier pricing is higher and not as prominent in marketing.
Annual cost at maintenance?
Variable — typically $1,788–$2,388/yr semaglutide, $2,988–$3,588/yr tirzepatide.
Are they trustworthy?
It's a real operation. The transparency criticism is about the dose-step pricing structure, not about clinical legitimacy.